The abstract of the patent application describes methods of administering an antitumor agent comprising deoxycytidine derivative. The methods are disclosed in the form of continuous intravenous infusion. The agent is 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone or a salt thereof, or 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone equivalent per day, for a duration of 168 to 336 hours. Compositions for providing the methods are also disclosed.
METHODS OF ADMINISTERING ANTITUMOR AGENT
COMPRISING DEOXYCYTIDINE DERIVATIVE

Technical Field

[0001] The present invention relates to an antitumor agent administered to cancer patients by intravenous infusion, and in some preferred embodiments, by continuous intravenous infusion.

Background Art

[0002] 4-amino-l-(2-cyano-2-deoxy- β-D-arabinofuranosyl)-2(IH)-pyrimidinone (CNDAC; See the Formula 1 below) is an antimetabolite in which the 2'-β position of deoxycytidine ribose is replaced by a cyano group.

[0003] [Formula 1]

[0004] CNDAC is a deoxycytidine analog, which at the time of filing of this application, is synthesized in Japan. Unlike deoxycytidine derivatives (gemcitabine) which are widely clinically used, CNDAC primarily causes DNA strand breaks. Specifically, it is considered that CNDAC is phosphorylated by intracellular deoxycytidine kinase, and thereby a triphosphorylated form (CNDACTP) is provided; that CNDACTP is incorporated into a DNA
strand, thus inducing hydrolysis and breaking the DNA strand; and that the cell cycle is thus arrested at the G2/M phase and the cell is killed. (See, for example, Japanese Patent Publication No. 2559917; J. Med. Chem., 1991, 34 (9): 2917 - 9; and J. Med. Chem, 1993, 36 (26): 4183 - 9.)

[0005] Most antitumor agents, which have an inhibitory effect on DNA synthesis as a main effect and are widely clinically used, demonstrate the effect as exhibiting the inhibitory effect at the S phase. Different from relatively fast-growing tumors used in animal tests, however, it has been identified that tumors grow slowly in clinical circumstances and that there are few cells in the S phase. Meanwhile, the antitumor effect of CNDAC, which is achieved by the DNA strand break effect, eventually arrests the cell cycle at the G2/M phase and thus kills tumor cells. Accordingly, it is considered that CNDAC can be differentiated from DNA synthesis inhibitors in wide clinical use, and that CNDAC is a clinically effective antitumor agent (Molecular Pharmacology, 2001, 59 (4): 725 - 31).

[0006] In order to achieve a higher antitumor effect of CNDAC for clinical use, it is necessary to develop a highly effective treatment method that enables continuous medication and surely prolongs patient survival.

Disclosure of the Invention

Technical Problems

[0007] The present invention solves the aforementioned problems by using CNDAC in a way that achieves a high antitumor effect and a low risk of causing toxicity that leads to interruption of continuous administration.
Technical Solution

[0008] As a result of extensive research on a method of using CNDAC by the inventors of the present invention, it was found that a high antitumor effect was achieved when CNDAC was administered by continuous intravenous infusion for a long period of time, and thus that the method of use would be an effective method in helping to prolong patient survival.

[0009] The invention provides, in some embodiments, an antitumor treatment regimen comprising: administering, to a patient diagnosed with cancer, an antitumor agent comprising 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone, or a salt thereof, by way of continuous intravenous infusion, in an amount of 2.0 to 4.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone equivalent, per day, for a duration of 168 to 336 hours. In some preferred embodiments, the antitumor agent is administered in an amount of 2.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone equivalent, per day, for a duration of 336 hours. In some preferred embodiments, the antitumor agent is administered in an amount of 3.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone equivalent, per day, for a duration of 168 hours. In some embodiments, a treatment course is performed at least twice, wherein the course comprises administering the antitumor agent by continuous intravenous infusion in an amount of 2.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone equivalent, per day, for a duration of 336 hours once every three weeks. In some embodiments, a treatment course is performed at least twice, wherein the course comprises administering the antitumor agent by continuous intravenous...
infusion in an amount of 3.0 mg per m² total body surface area of the patient, of 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(IH)-pyrimidinone equivalent, per day, for a duration of 168 hours once every two weeks.

[0010] The invention also provides a composition for continuous intravenous administration of an antitumor agent to a patient comprising a container comprising 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(IH)-pyrimidinone, or a salt thereof, diluted in a physiologically acceptable fluid medium for delivering intravenous antitumor agents, to a concentration sufficient to provide an amount of 2.0 to 4.0 mg per m² total body surface area of the patient, of 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(IH)-pyrimidinone equivalent, per day, for a duration of 168 to 336 hours. In some preferred embodiments, the concentration of the antitumor agent is sufficient to provide an amount of 2.0 mg per m² total body surface area of the patient, of 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(IH)-pyrimidinone equivalent, per day, for a duration of 336 hours. In some preferred embodiments, the concentration of the antitumor agent is sufficient to provide an amount of 3.0 mg per m² total body surface area of the patient, of 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(IH)-pyrimidinone equivalent, per day, for a duration of 168 hours.

[0011] The invention also provides a composition for continuous intravenous administration of an antitumor agent to a patient, comprising a container comprising 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(IH)-pyrimidinone, or a salt thereof, diluted in a physiologically acceptable fluid medium for delivering intravenous antitumor agents, to a concentration sufficient to provide an amount of 2.0 to 4.0 mg per m² total body surface area of the patient, of
4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(lH)-pyrimidinone equivalent, per day, for a duration of 168 to 336 hours.

[0012] The invention also provides use of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(lH)-pyrimidinone or a salt thereof for the production of an antitumor agent, wherein the antitumor agent is administered to a patient, by way of continuous intravenous infusion, in an amount of 2.0 to 4.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(lH)-pyrimidinone equivalent, per day, for a duration of 168 to 336 hours.

Advantageous Effects

[0013] The antitumor agent according to the present invention is capable of achieving a high antitumor effect while reducing risk of side effects, mainly including body weight suppression and leucopenia. In other words, the antitumor agent has a low risk of interrupting treatment due to side effects and provides a high treatment effect so as to surely prolong patient survival.

Brief Description of the Figures

[0014] The present invention is further described in the description of invention that follows, in reference to the noted plurality of non-limiting drawings, wherein:

[0015] FIGURE 1 shows the antitumor effect in rapid intravenous infusion and continuous intravenous infusion of CNDAC administered to tumor-bearing rats having the human lung cancer line LX-I.
[0016] FIGURE 2 shows the antitumor effect in continuous intravenous infusion of CNDAC and gemcitabine administered to tumor-bearing rats having the human colon cancer line KM20C.

[0017] FIGURE 3 shows the antitumor effect in continuous intravenous infusion of CNDAC administered to tumor-bearing rats having the human pancreatic cancer line PAN-4.


Detailed Description of the Invention

[0019] Unless otherwise stated, a reference to a compound or component includes the compound or component by itself, as well as in combination with other compounds or components, such as mixtures of compounds.

[0020] As used herein, the singular forms "a," "an," and "the" include the plural reference unless the context clearly dictates otherwise.

[0021] Except where otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term "about." Accordingly, unless indicated to the contrary, the numerical parameters set forth in the following specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not to be considered as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter
should be construed in light of the number of significant digits and ordinary rounding conventions.

[0022] Additionally, the recitation of numerical ranges within this specification is considered to be a disclosure of all numerical values within that range. For example, if a range is from about 1 to about 50, it is deemed to include, for example, 1, 7, 34, 46.1, 23.7, or any other value within the range.

[0023] The present inventors have discovered that CNDAC exhibits a strong antitumor effect against a wide range of tumor lines. It was found in antitumor tests using animal models that CNDAC demonstrated strong antitumor and antiproliferative effects on a majority of human-derived tumor lines when administered by rapid intravenous infusion for 10 consecutive days, five times a week for two weeks, and once a week for two weeks. However, the regrowth of tumors was observed after completion of the administration, and the cytoreductive effect was not necessarily shown. Further, increasing the dosage so as to increase the antitumor effect causes toxicity, including body weight suppression and leucopenia.

[0024] As a result of extensive research on a method of using CNDAC by the inventors of the present invention, it was found that a high antitumor effect was achieved when CNDAC was administered by continuous intravenous infusion for a long period of time, and thus that the method of use would be an effective method in helping to prolong patient survival.

[0025] CNDAC, which is an active ingredient of the antitumor agent according to the present invention, is a known compound indicated as 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(IH)-pyrimidinone. It is known that the compound has an antitumor effect on many cancer types by its DNA strand break effect. It is described in Biochemical
Pharmacology, 2001; 61 (12): 1497 - 507, that contacting CNDAC with tumor cells for a long time enhances the inhibitory effect on cell growth. It is not suggested, however, that cancer can be effectively treated while development of side effects is inhibited.

[0026] As a salt of CNDAC, any pharmaceutically acceptable salts can be used, such as, for example, inorganic and organic acid salts. Inorganic acid salts include hydrochloride, hydrobromate, sulfate, nitrate, phosphate, and the like. Organic acid salts include acetate, propionate, tartrate, fumarate, maleate, malate, citrate, methanesulfonate, p-toluenesulfonate, trifluoroacetate, and the like. Among the salts above, hydrochloride or acetate is preferable.

[0027] CNDAC according to the present invention and the salt thereof can be manufactured by any method, examples of which are known, such as, for example, a method described in Japanese Patent Publication No. 2559917.

[0028] The antitumor agent according to the present invention is administered intravenously. The agent is administered in form of injections. Injections may be liquid injections or solid injections, such as, lyophilized injections, which are dissolved when used, powder injections, and the like.

[0029] The antitumor agent according to the present invention can be prepared in any procedure, examples of which are known, in which pharmacologically acceptable carriers are added to CNDAC or the salt thereof. A variety of organic and inorganic carrier materials commonly used as pharmaceutical materials can be used as the carriers. For solid injections, excipients, lubricants, binders, disintegrants, and the like can be added. For liquid injections, diluents, auxiliary dissolvents, suspenders, tonicity agents, pH adjusters, buffers, stabilizers, soothing
agents, and the like can be added. In addition, pharmaceutical additives, such as antiseptics, antioxidants, colorants, and the like, can be used when necessary.

Excipients may include, for example, lactose, sucrose, sodium chloride, glucose, maltose, mannitol, erythritol, xylitol, maltitol, inositol, dextran, sorbitol, albumin, urea, starch, calcium carbonate, kaolin, crystalline cellulose, silicic acid, methylcellulose, glycerin, alginate sodium, gum arabic, and mixtures of the above-listed ingredients. Lubricants may include, for example, purified talc, stearate, borax, polyethylene glycol, and mixtures of the above-listed ingredients. Binders may include, for example, simple syrups, dextrose solutions, starch solutions, gelatin solutions, polyvinyl alcohol, polyvinyl ether, polyvinylpyrrolidone, carboxymethylcellulose, shellac, methylcellulose, ethylcellulose, water, ethanol, potassium phosphate, and mixtures of the above-listed ingredients. Disintegrants may include, for example, dry starch, alginate sodium, powdered agar, powdered laminaran, sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, monoglyceride stearate, starch, lactose, and mixtures of the above-listed ingredients. Diluents may include, for example, water, ethyl alcohol, macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxidized isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters, and mixtures of the above-listed ingredients. Stabilizers may include, for example, sodium pyrosulfite, ethylenediaminetetraacetic acid, thioglycolic acid, thiolactic acid, and mixtures of the above-listed ingredients. Tonicity agents may include, for example, sodium chloride, boric acid, glucose, glycerin, and mixtures of the above-listed ingredients. PH adjusters and buffers may include, for example, sodium citrate, citric acids, sodium acetate, sodium phosphate, and mixtures of the above-listed ingredients.
Soothing agents may include, for example, procaine hydrochloride, lidocaine hydrochloride, and mixtures of the above-listed ingredients.

[0031] A preferable dosage of the antitumor agent according to the present invention is 2.0 to 3.0 mg per m² total body surface area of the patient (also presented herein as mg/m²) of CNDAC equivalent per day, in terms of a relation between the risk of side-effects development and antitumor effect.

[0032] In view of effective cancer treatment with inhibition of side-effects development, including body weight suppression and leucopenia, it is preferable to administer the antitumor agent of the present invention for a duration of 168 to 336 hours when the dosage per day is 2.0 mg/m² of CNDAC equivalent. It is more preferable to administer the antitumor agent for a duration of 336 hours. When the dosage per day is 3.0 mg/m² of CNDAC equivalent, it is preferable to administer the antitumor agent for a duration of 168 hours.

[0033] In order to reduce toxicity and achieve a better antitumor effect, it is preferable to administer the antitumor agent of the present invention intravenously in a repeated manner in a course of a series of administration schedule. A preferable administration schedule is that a course is performed, one time or a plurality of repeated times, in which the antitumor agent is administered by continuous intravenous infusion in an amount of 2.0 to 4.0 mg/m² of CNDAC equivalent per day for a duration of 336 hours once every three weeks; and that a course is performed, one time or a plurality of repeated times, in which the antitumor agent is administered by continuous intravenous infusion in an amount of 3.0 to 4.0 mg/m² of CNDAC equivalent per day for a duration of 168 hours once every two weeks. It is more preferable that a course is performed, one time or a plurality of repeated times, in which the antitumor agent is
administered by continuous intravenous infusion in an amount of 2.0 mg/m² of CNDAC equivalent per day for a duration of 336 hours once every three weeks; and that a course is performed, one time or a plurality of repeated times, in which the antitumor agent is administered by continuous intravenous infusion in an amount of 3.0 mg/m² of CNDAC equivalent per day for a duration of 168 hours once every two weeks.

[0034] The antitumor agent of the present invention can be applied to non-limiting cancer types, including head and neck cancer, esophagus cancer, stomach cancer, colorectal cancer, liver cancer, gallbladder and bile duct cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, bladder cancer, prostate cancer, testis tumor, bone and soft-tissue sarcoma, malignant lymphoma, leukemia, cervical cancer, skin cancer, brain tumor, and the like. It is particularly preferable to apply the antitumor agent to head and neck cancer, breast cancer, lung cancer, stomach cancer, colorectal cancer, pancreatic cancer, and bladder cancer.

[0035] The antitumor agent of the present invention may be administered to patients who have never undergone cancer treatment, currently treated patients, and previously treated patients.

[0036] The antitumor agent of the present invention can be administered concurrently with other antitumor agents and/or radiation. Antitumor agents that can be administered concurrently may include, for example, 5-FU, tegafur/uracil preparations, tegafur/gimeracil/oteracil potassium preparations, doxorubicin, epirubicin, irinotecan hydrochloride, etoposide, docetaxel, paclitaxel, cisplatin, carboplatin, oxaliplatin, krestin, lentinan, picibanil, and the like.

Examples

[0037] It is to be understood that while the invention has been described in conjunction with certain preferred and/or specific embodiments, the foregoing description as well as the examples
that follow are intended to illustrate and not limit the scope of the invention. Other aspects, advantages, and modifications within the scope of the invention will be apparent to those skilled in the art to which the invention pertains.

[0038] AU chemical reagents referred to in the appended examples are commercially available unless otherwise indicated.

[0039] Example 1

[0040] The frequency of adverse events and treatment effect were studied in a case where a course was repeatedly performed in which the antitumor agent was administered to cancer patients by continuous intravenous infusion in an amount of 2.0 to 4.0 mg/m²/day of CNDAC (free base) for a duration of 336 hours once every three weeks.

[0041] The present test was conducted on patients having a variety of solid cancers for which standard treatment was ineffective or no treatment was available (e.g., digestive system cancer, head and neck cancer, breast cancer, and the like). The test is equivalent to the Clinical Phase I Test, which primarily evaluates safety so as to determine a recommended dose (RD) that can be safely administered with no side effect concerns in the Clinical Phase II Test implemented per cancer type. Treatment effect on tumors was also evaluated in the test when possible. In the treatment effect test, the cytoreductive effect was determined based on comprehensive evaluation of target lesions (lesions having a size measurable at a slice width on CT and a larger size) and non-target lesions (all lesions not included in the target lesions), with reference to the RECIST evaluation method (Journal of the National Cancer Institute, 2000, Vol. 92, No. 3, 205 - 216). In the present test, PR (partial response) indicates a case where a reduction of 30% or more in the sum of the longest diameter of target lesions was demonstrated, compared with the sum of the
longest diameter of pre-administration; the effect was maintained for a predetermined period (normally four weeks); and non-target lesions did not exacerbate during the period. PD (progression disease) indicates a case where an increase of 20% or more in the sum of the longest diameter of target lesions was demonstrated, compared with the smallest sum of the longest diameter recorded since the start of the test; or existing non-target lesions obviously exacerbated, or new lesions were recognized. SD (stable disease) indicates a case where reduction of tumors was not enough to be determined as PR, but insufficient to be determined as PD; and the progression of tumors stopped and no exacerbation was observed.

[0042] As results of administration of a continuous intravenous infusion of CNDAC preparations (injection) in an amount of 2.0 to 4.0 mg/m²/day for a duration of 336 hours once every three weeks, dose limiting toxicity (DLT) was observed in three out of three cases (100%) (febrile neutropenia of CTCAE Grade 3 in all cases; platelet reduction of Grade 4 in one out of the three cases) when 4.0 mg/m²/day was administered, and thus administration of a minimum of two courses as defined in the implementation plan could not be completed. Further, although DLT was not observed when 3.0 mg/m²/day was administered, neutropenia of Grades 3 and 4 was found in the second case each of two courses, and thus the dosage needed to be reduced in one case. The efficacy (SD) was demonstrated in one out of the three cases. Meanwhile, when 2.0 mg/m²/day was administered, no adverse event was seen that required interruption of the administration. SD was demonstrated in four out of six cases (66%), for which the efficacy could be evaluated, and one case among the cases demonstrated a reduction of about 15%.

[0043] Accordingly, it was concluded in the CNDAC administration that continuous intravenous infusion was an administration method that achieved a high efficacy while inhibiting toxicity
development, the continuous intravenous infusion being administered to patients having a variety of solid cancers (e.g., digestive system cancer, lung cancer, bladder cancer, and the like) for which standard treatment was ineffective or no treatment was available.

[0044] Example 2

[0045] The frequency of adverse events and treatment effect were studied in a case where a course was repeatedly performed in which the antitumor agent was administered by continuous intravenous infusion in an amount of 3.0 to 4.0 mg CNDAC (free base) per square meter of body surface area per day for a duration of 168 hours once every two weeks. Tested patients, evaluation methods, and evaluation standards are the same as those in the test in Example 1.

[0046] As results of administration of a continuous intravenous infusion of CNDAC preparations (injection) in an amount of 3.0 to 4.0 mg/m²/day for a duration of 168 hours once every two weeks, when 4.0 mg/m²/day was administered, dose limiting toxicity (DLT) was observed in two out of three cases (67%), for which the safety could be evaluated (febrile neutropenia of CTCAE Grade 3 in one case; neutropenia of Grade 4 in one case). The efficacy (SD) was demonstrated in two out of the three cases (67%), for which the safety could be evaluated. Meanwhile, when 3.0 mg/m²/day was administered, no adverse event was seen that required interruption of the administration. SD was demonstrated in two out of eight cases (25%), for which the efficacy could be evaluated.

[0047] Accordingly, it was concluded in the CNDAC administration that continuous intravenous infusion was an administration method that achieved a high efficacy while inhibiting toxicity development, the continuous intravenous infusion being administered to patients having a variety
of solid cancers (e.g., digestive system cancer, and head and neck cancer) for which standard treatment was ineffective or no treatment was available.

[0048] Example 3

[0049] The antitumor effect was studied in rapid intravenous infusion and continuous intravenous infusion of CNDAC in tumor-bearing rat models. Fig. 1 indicates the study results of the antitumor effect in rapid intravenous infusion and continuous intravenous infusion of CNDAC administered to tumor-bearing rats having the human lung cancer line LX-I.

[0050] CNDAC (free base) was administered by rapid intravenous infusion (rapidly injected into a caudal vein using a syringe) in an amount of 800 mg/kg/day on Days 1 to 5 and 8 to 12, or 20 mg/kg/day on Days 1 and 8. Alternatively, CNDAC was administered by continuous intravenous infusion (continuously injected under the skin for 24 hours using a subcutaneous implantation constant-speed pump) in an amount of 4.5 mg/kg/day for two weeks. Relative tumor volume (a ratio of tumor volume on Day 1 of administration and that on Day 14 of administration) was obtained in a CNDAC administered group and a non-administered group (control group) of each administration method, and the obtained relative tumor volume was compared. A high antitumor effect was demonstrated in the continuous intravenous infusion, compared with the rapid intravenous infusion. The effect was exhibited not only in the human lung cancer line, but also in human breast cancer and colon cancer lines.

[0051] Example 4

[0052] The antitumor effect was studied in a continuous intravenous infusion of CNDAC and gemcitabine administered to tumor-bearing rats having the human colon cancer line KM20C. Fig. 2 indicates the results.
CNDAC was administered by continuous intravenous infusion (continuously injected under the skin for 24 hours using a subcutaneous implantation constant-speed pump) in an amount of 36 mg/kg/day on Days 1 and 8, or 4.5 mg/kg/day on Days 1 to 14. Alternatively, gemcitabine was administered by rapid intravenous infusion in an amount of 300 mg/kg/day once a week for two weeks (Days 1 and 8), or by continuous intravenous infusion in an amount of 1.0 mg/kg/day for two weeks. Relative tumor volume was obtained and compared in a drug administered group and a non-administered group (control group) of each administration method. In the continuous intravenous infusion of CNDAC, the tumor volume was significantly reduced even after the administration was completed. In contrast, in the continuous intravenous infusion of gemcitabine, which is a deoxycytidine derivative having a similar structure as CNDAC, the tumor volume was not reduced after the administration was completed. The results indicate that administering CNDAC at low doses for a long period of time enhanced the antitumor effect extremely strongly beyond expectation, compared with the enhancement by gemcitabine.

Example 5

A relation between the antitumor effect and side effect (body weight suppression) was studied in a continuous intravenous infusion of CNDAC administered to tumor-bearing rats having the human pancreatic cancer line PAN-4. Figs. 3 and 4 indicate the results.

CNDAC was administered by continuous intravenous infusion (continuously injected under the skin for 24 hours using a subcutaneous implantation constant-speed pump) in an amount of 36 mg/kg/day on Day 1, or 4.5 mg/kg/day on Days 1 to 14. Relative tumor volume was obtained and compared in a CNDAC administered group and a non-administered group (control group) of each administration method. A significantly high antitumor effect was
demonstrated in the two-week continuous intravenous infusion, compared with the 24-hour
continuous intravenous infusion.

[0057] Further, body weight reduction in the two-week continuous intravenous infusion group
and 24-hour continuous intravenous infusion group was studied. A body weight reduction of as
much as 20.4% at maximum was confirmed in the 24-hour continuous intravenous infusion
group, while the body weight reduction was 4.6% even at maximum in the two-week continuous
intravenous infusion. The results indicate that the long-term continuous intravenous infusion
provided a significantly high antitumor effect while sufficiently reducing the side effect (body
weight reduction).

[0058] The specification is most thoroughly understood in light of the teachings of the
documents cited within the specification, all of which are hereby incorporated by reference in
their entirety. The embodiments within the specification provide an illustration of embodiments
of the invention and should not be construed to limit the scope of the invention. The skilled
artisan recognizes that many other embodiments are encompassed by the claimed invention and
that it is intended that the specification and examples be considered as exemplary only, with a
true scope and spirit of the invention being indicated by the following claims.
Claims

1. An antitumor treatment regimen comprising: administering, to a patient diagnosed with cancer, an antitumor agent comprising 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(lH)-pyrimidinone, or a salt thereof, by way of continuous intravenous infusion, in an amount of 2.0 to 4.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(lH)-pyrimidinone equivalent, per day, for a duration of 168 to 336 hours.

2. The antitumor treatment regimen according to claim 1, wherein the antitumor agent is administered in an amount of 2.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(lH)-pyrimidinone equivalent, per day, for a duration of 336 hours.

3. The antitumor treatment regimen according to claim 1, wherein the antitumor agent is administered in an amount of 3.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(lH)-pyrimidinone equivalent, per day, for a duration of 168 hours.

4. The antitumor treatment regimen according to claim 1, wherein a treatment course is performed at least twice, wherein the course comprises administering the antitumor agent by continuous intravenous infusion in an amount of 2.0 mg per m² total body surface area of the patient.
patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(lH)-pyrimidinone equivalent, per day, for a duration of 336 hours once every three weeks.

5. The antitumor treatment regimen according to claim 1, wherein a treatment course is performed at least twice, wherein the course comprises administering the antitumor agent by continuous intravenous infusion in an amount of 3.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(lH)-pyrimidinone equivalent, per day, for a duration of 168 hours once every two weeks.

6. A composition for continuous intravenous administration of an antitumor agent to a patient, comprising 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(lH)-pyrimidinone, or a salt thereof, at a concentration sufficient to provide an amount of 2.0 to 4.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(lH)-pyrimidinone equivalent, per day, for a duration of 168 to 336 hours.

7. The composition for continuous intravenous administration of an antitumor agent according to claim 6, wherein the concentration of the antitumor agent is sufficient to provide an amount of 2.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(lH)-pyrimidinone equivalent, per day, for a duration of 336 hours.
8. The composition for continuous intravenous administration of an antitumor agent according to claim 6, wherein the concentration of the antitumor agent is sufficient to provide an amount of 3.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(lH)-pyrimidinone equivalent, per day, for a duration of 168 hours.

9. The composition for continuous intravenous administration of an antitumor agent according to claim 6, wherein the concentration of the antitumor agent is sufficient to provide an amount of 2.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(lH)-pyrimidinone equivalent, per day, for a duration of 336 hours, which is administered to the patient once every three weeks as one treatment course and wherein the treatment course is performed at least twice.

10. The composition for continuous intravenous administration of an antitumor agent according to claim 6, wherein the concentration of the antitumor agent is sufficient to provide an amount of 3.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(lH)-pyrimidinone equivalent, per day, for a duration of 168 hours, which is administered to the patient once every two weeks as one treatment course and wherein the treatment course is performed at least twice.

11. A composition for continuous intravenous administration of an antitumor agent to a patient, comprising a container comprising 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-
2(H)-pyrimidinone, or a salt thereof, diluted in a physiologically acceptable fluid medium for delivering intravenous antitumor agents, to a concentration sufficient to provide an amount of 2.0 to 4.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(H)-pyrimidinone equivalent, per day, for a duration of 168 to 336 hours.

12. The composition for continuous intravenous administration of an antitumor agent according to claim 11, wherein the concentration of the antitumor agent is sufficient to provide an amount of 2.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(H)-pyrimidinone equivalent, per day, for a duration of 336 hours.

13. The composition for continuous intravenous administration of an antitumor agent according to claim 11, wherein the concentration of the antitumor agent is sufficient to provide an amount of 3.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(H)-pyrimidinone equivalent, per day, for a duration of 168 hours.

14. Use of 4-amino-l-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(H)-pyrimidinone or a salt thereof for the production of an antitumor agent, wherein the antitumor agent is administered to a patient, by way of continuous intravenous infusion, in an amount of 2.0 to 4.0 mg per m²
total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy- β-D-arabinofuranosyl)-2(1H)-pyrimidinone equivalent, per day, for a duration of 168 to 336 hours.

15. The use according to claim 14, wherein the antitumor agent is administered in an amount of 2.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy- β-D-arabinofuranosyl)-2(1H)-pyrimidinone equivalent, per day, for a duration of 336 hours.

16. The use according to claim 14, wherein the antitumor agent is administered in an amount of 3.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy- β-D-arabinofuranosyl)-2(1H)-pyrimidinone equivalent, per day, for a duration of 168 hours.

17. The use according to claim 14, wherein the antitumor agent is administered in an amount of 2.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy- β-D-arabinofuranosyl)-2(1H)-pyrimidinone equivalent, per day, for a duration of 336 hours once every three weeks as one treatment course and wherein the treatment course is performed at least twice.

18. The use according to claim 14, wherein the antitumor agent is administered in an amount of 3.0 mg per m² total body surface area of the patient, of 4-amino-l-(2-cyano-2-deoxy- β-D-arabinofuranosyl)-2(1H)-pyrimidinone equivalent, per day, for a duration of 168 hours once every two weeks as one treatment course and wherein the treatment course is performed at least twice.
Figure 1

- Control
- CNDAC i.v. day 1,5,8,12 800mg/kg
- CNDAC day1-5,8-12 20mg/kg
- CNDAC 14days CI 4.5mg/kg/day
Figure 2

KM20C/nude mouse subcutaneous implantation model

- ■: CNDAC 36mg/kg/day
  24hr infusion (Day 1, 8)
- ■: CNDAC 4.5mg/kg/day
  14-day insusion
- ◆: Gemcitabine 300mg/kg/day
  i.v. bolus (Day 1, 8)
- ◆: Gemcitabine 1mg/kg/day
  14-day insusion
Human pancreatic cancer line PAN-4
- Antitumor effect -

<table>
<thead>
<tr>
<th></th>
<th>IR(%) on Day 29</th>
<th>Max. body weight reduction (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>24hr infusion</td>
<td>39.5</td>
<td>-20.4</td>
</tr>
<tr>
<td>14day infusion</td>
<td>88.9</td>
<td>-4.6</td>
</tr>
</tbody>
</table>

○: CNDAC 60mg/kg/day 24hr infusion (Day 1)
●: CNDAC 4.5mg/kg/day 14-day infusion (Day 1-14)
Figure 4

**Human pancreatic cancer line PAN-4**
- Antitumor effect -

O : CNDAC 60mg/kg/day 24hr infusion (Day 1)
● : CNDAC 4.5mg/kg/day 14-day infusion (Day 1-14)
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K31/7068 A61P35/00
According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, WPI Data, BIOSIS, EMBASE, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>EP 0 535 231 A (SANKYO CO [JP]) 7 April 1993 (1993-04-07) page 29; example 8 page 36; claim 11 page 35, line 1 - line 5 page 35, lines 5,8 - line 10</td>
<td></td>
</tr>
</tbody>
</table>

X Further documents are listed in the continuation of Box C. X See patent family annex.

* Special categories of cited documents:
  *A* document defining the general state of the art which is not considered to be of particular relevance
  *E* earlier document but published on or after the international filing date
  *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  *O* document referring to an oral disclosure, use, exhibition or other means
  *P* document published prior to the international filing date but later than the priority date claimed

* "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
* "A" document member of the same patent family

Date of the actual completion of the international search 28 September 2009

Date of mailing of the international search report 06/10/2009

Name and mailing address of the ISA
European Patent Office, P.B. 5816 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016

Authorized officer
Opravz, Petra
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>WO 2005/053699 A (CYCLACEL LTD [GB]; GREEN SIMON [GB]; SLEIGH ROGER NEIL [GB]) 16 June 2005 (2005-06-16) page 11, line 19 - line 20 page 11, line 25 - line 26 page 20; claims 1,5,8,13-16</td>
<td></td>
</tr>
</tbody>
</table>
### INTERNATIONAL SEARCH REPORT

**Information on patent family members**

<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>CA 2085345 A1</td>
<td>16-12-1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69109482 D1</td>
<td>08-06-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DE 69109482 T2</td>
<td>15-02-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 0535231 T3</td>
<td>21-08-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2074719 T3</td>
<td>16-09-1995</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HK 1005871 A1</td>
<td>29-01-1999</td>
</tr>
<tr>
<td></td>
<td></td>
<td>HU 62582 A2</td>
<td>28-05-1993</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 9119713 A1</td>
<td>26-12-1991</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2559917 B2</td>
<td>04-12-1996</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 4235182 A</td>
<td>24-08-1992</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RU 2116306 C1</td>
<td>27-07-1998</td>
</tr>
<tr>
<td>WO 2007132228 A</td>
<td>22-11-2007</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2007513132 T</td>
<td>24-05-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>US 2007270442 A1</td>
<td>22-11-2007</td>
</tr>
</tbody>
</table>

Form PCT/ISA/210 (patent family annex) (April 2005)